The company was originally incorporated as Laurus Labs Private Limited on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company under the Companies Act, 1956. The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited and a fresh certificate of incorporation consequent upon change of name on conversion to a public limited company was issued by the Registrar of Companies, Andhra Pradesh and Telangana, located at Hyderabad (RoC) on February 12, 2007. Subsequently the name of the company was changed to Aptuit Laurus Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on July 19, 2007. Thereafter, the cmpany was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited and a fresh certificate of incorporation consequent upon change of name on conversion to a private limited company was issued by the RoC on July 24, 2007. Subsequently the name of the company was changed to Laurus Labs Private Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on February 21, 2012. The company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited and a fresh certificate of incorporation consequent upon change of name on conversion to a public limited company was issued by the RoC on August 16, 2016.
Laurus Labs Limited is a public company domiciled in India and is incorporated under the provisions of the Companies Act applicable in India. Its shares are listed on two recognised stock exchanges in India. Laurus Labs develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality and affordability. It works with all the top generic pharmaceutical companies in the world. The company sells its APIs in many countries. Its major focus areas include anti-retroviral, Hepatitis C and Oncology drugs. Continuous innovation is the lifeblood of its business. Therefore, it undertake dedicated R&D in areas that have significant growth potential. The company has commercialised various products since inception across three distinct business units: Generics API, Generics FDF and Synthesis.
Business area the company
Laurus Labs offers broad and integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry.
Business units
Generics API
Generics FDF
Ingredients
Synthesis
Facilities
Awards
2017-18
Laurus wins ‘API Supplier of the Year’ Award- Laurus Labs has been named as the ‘API Supplier of the Year- 2017’ at the Global Generics and Biosimilars Awards. These awards recognize companies that implement best practices in the global pharmaceutical industry.
National Safety Award- Laurus Labs received the prestigious National Safety Award for best safety performance from DGFASLI, Ministry of Labour and Employment, Government of India.
Laurus Labs certified as ‘Great Place to Work’ for the year 2018- Laurus Labs has been certified as a ‘Great Place to Work’, in the large-sized organization category in India, in the 2018 edition of Great Place to Work - a study by the Great Place to Work Institute. It is an important step for the organisation in its journey to build a high-trust, high performance culture.
2018-19
Best Work Places- Laurus Labs is recognised as one of the Best Work Places in Biotechnology, Pharmaceuticals & Health Care sectors for the year 2018.
Express Pharma Excellence Award 2019- Laurus Labs received the Indian Express Pharma Excellence Award 2019.
Global Generics and Biosimilars API Supplier of the Year Award- Laurus Labs won the Global Generics and Biosimilars API Supplier of the Year award. The award was presented by Generics Bulletin - in association with IQVIA - at the Palacio Municipal de Congresos, Madrid on October 9, 2018.
IconSWM Excellence Award 2018 Laurus Labs received the ‘IconSWM Excellence Award 2018’ for the excellence shown in Resource-efficient Industry. IconSWM stands for International Conference on Sustainable Waste Management. 8th IconSWM conference organised with the collaboration of the Andhra Pradesh government.
2019-20
National Safety Award- The company (Unit 1 and Unit 3) won the prestigious National Safety Award for best safety performance for 2017 from DGFASLI, Ministry of Labour and Employment, Government of India.
Pharmexcil Award- Laurus Labs the Pharmexcil Outstanding Export Performance Award 2018 -19.
Great Place to Work- Laurus Labs was certified as Great Place to Work for the second consecutive year in 2019-20.
Fortune 500 Company- Laurus Labs continue to feature in the Fortune 500 Companies List in India since 2017.
Milestones
2007
Set up API manufacturing facility Unit-I at Visakhapatnam
Secured investment from Aptuit Singapore of Rs 1.02 billion
Executed manufacturing and services agreements with three multinational companies
Commenced operations at its R&D Centre
2008
Filed its first-ever Drug Master File
Commenced operations at Unit-I
Supplied company’s first product to the US
2009
DSIR recognised its R&D Centre
Commercialised four nutritional fine chemicals
Launched first product in Europe
Entered into a license agreement with an international organisation and a multinational company to manufacture and sell its products in the ARV segment
2010
2011
2012
Secured investment of INR 490 million from FIL Capital Management and FIP through primary investment and
Secondary acquisition of Aptuit’s majority stake along with additional investments by one of its promoters
2013
2014
Acquired 135 acres in Visakhapatnam for expansion
Received an investment of Rs 3000 million from Bluewater
Commenced construction of Unit 2
Incorporated Laurus Inc. in Delaware, US as a wholly-owned subsidiary
2015
Commenced commercial operations at Unit 3, Visakhapatnam
Acquired 27% stake in Sriam Labs Private Limited, Hyderabad
Successful inspection by WHO, NIP Hungary and US FDA for Unit 1 and Unit 3 manufacturing sites
2016
Successful USFDA inspection of the kilo-lab facility at its R&D Centre
Received approval from BfArM Germany for Unit 2 at Vishakhapatnam
Crossed Rs 15 billion in revenues
Filed first ANDA with the USFDA and first dossier with the WHO
2017
Successful USFDA inspection of Unit 1, 2 & 3 API manufacturing facilities with no critical observations. (Unit 2 has no 483 observations)
Successful WHO inspection of Units 1, 2 & 3
Successful BGV Hamburg (German Regulatory Authority) inspection of Unit 2 (FDF) with no critical or major observations
2018
Crossed INR 20 billion of revenue. Commenced commercial operations from Unit 4.
Incorporated a subsidiary in Germany.
Unit 2-Formulations, inspected by USFDA with Zero 483 observations.
Launched maiden FDF product Tenofovir in USA, Canada and emerging markets.
Certified as Great Place to Work for the year 2018.
2019
Unit 6 - EIR Received from USFDA
Entered into Strategic partnership with Global Fund for 3.5 years.
Executed a major tender order and delivered ahead of schedule
Executed highest on-time delivery in FDF orders.
Maiden EIR received for Unit 4
2020
Incorporated Laurus Synthesis Pvt. Ltd
Acquired assets of an API Unit in Vizag
Acquired Aspen’s South Africa Subsidiary - Laurus Generics SA(PTY) Limited
2021
Comment